Petlife Corporation completed the acquisition of Eco Ventures Group, Inc. in a reverse merger transaction.
August 11, 2014 at 05:00 am
Share
Petlife Corporation entered into a share exchange agreement to acquire Eco Ventures Group, Inc. (OTCPK:EVGI) in a reverse merger transaction on April 17, 2014. Under the agreement, Eco Ventures will issue 40 million shares as consideration, representing 80% of the issued and outstanding shares of Eco Ventures, resulting in change of control. Eco Ventures will change the name to Petlife Inc and both the CUSIP number and trading symbol of Eco Ventures, which trades on the OTCQB Tier of the OTC Markets, will change as a result of the name change. The Directors of Petlife shall be appointed to the Board of Directors of Eco Ventures and shall constitute the majority of the Board.
Randall Lanham, sole Director of Eco Ventures shall resign from his seat on the Board of Directors and respective positions as officer of Eco Ventures. The Board of Directors of Petlife has approved this agreement, recommend shareholders of Petlife to vote in favour of the transaction. The Board of Directors of Eco Ventures has approved the share exchange transaction. The transaction is subject to receipt of Petlife and Eco Ventures' shareholders approval, regulatory and other third party consents, permits, approvals. As of August 7, 2014, Eco Ventures changed its name to PetLife Pharmaceuticals, Inc. Also, Eco Ventures is now current in its SEC filings and expects to seek relisting on the OTCQB. Eco Ventures also completed 1-for-20 stock split. On June 26, 2014, Clear TV Ventures, Inc became Petlife Pharmaceuticals, Inc.
Davisson & Associates, PA acted as escrow agent and Empire Stock Transfer, Inc. acted as transfer agent to Eco Ventures. Mark Rabinovich of Law Offices of Mark Rabinovich, PC acted as legal advisor to Petlife. Peder K. Davisson of Davisson & Associates, PA acted as legal advisor to Eco Ventures.
Petlife Corporation completed the acquisition of Eco Ventures Group, Inc. (OTCPK:EVGI) in a reverse merger transaction on August 11, 2014.
PetLife Pharmaceuticals, Inc. is a veterinary pharmaceutical company. The Company specializes in the research, development, sales and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis. The Company has developed and is launching veterinary cancer medications and nutraceuticals, based on the Escozine formula. The Company has rights to formulate, package and market a product line, Vitalzul. Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins and minerals. Vitalzul inhibits blood vessels formation in solid tumors. Escozine has been used in combination with chemotherapy, radiation, hormone therapy and other conventional treatments. As of August 31, 2016, Escozine (for humans) was sold as either a nutraceutical or prescription drug in 40 countries, including the United States.
PETLIFE PHARMACEUTICALS, INC. 
